在患有慢性心力衰竭的患者中,用静脉注射免疫球蛋白进行免疫调节疗法
L Gullestad1, H Aass, J G Fjeld
1Department of Cardiology, Medical Department, Rikshospitalet, Oslo, Norway.
Circulation
|February 24, 2001
概括
静脉注射免疫球蛋白 (IVIG) 治疗减少了炎症,改善了 Left Ventricular Ejection Fraction (LVEF) 在充血性心力衰竭 (CHF) 患者中. 这表明IVIG作为一种潜在的免疫调节治疗CHF.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 充血性心力衰竭 (CHF) 呈现出高度的免疫激活,这表明免疫介导的发病.
- 静脉注射免疫球蛋白 (IVIG) 具有免疫调节的特性.
- 假设:IVIG可以降低炎症并改善CHF患者的左心室喷射率 (LVEF).
研究的目的:
- 研究IVIG对慢性症状性CHF患者的炎症标志物和LVEF的影响.
- 确定IVIG是否可以调节CHF中促炎和抗炎细胞因子的平衡.
主要方法:
- 这是一项双盲,安慰剂控制的研究,涉及40名CHF患者,LVEF<40%.
- 患者接受IVIG或安慰剂治疗26周.
- 测量包括血细胞因子水平,LVEF和N-终端前庭 natriuretic .
主要成果:
- IVIG显著增加了抗炎媒介 (IL-10,IL-1受体对抗剂,可溶性瘤亡因子受体).
- 通过IVIG治疗导致LVEF显著增加 (从26±2%增加到31±3%),独立于CHF的原因.
- 随着IVIG治疗,N-终端前性尿水平显著下降.
结论:
- 在CHF患者中,IVIG将细胞因子平衡转向抗炎状态.
- 观察到的抗炎作用与改善的LVEF相关.
- IVIG显示出作为治疗心血管衰竭的辅助免疫调节疗法的潜力.
相关概念视频
01:21Stem Cell Therapy for Tissue Regeneration
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.